NON-AQUEOUS GLUCAGON FORMULATIONS
Stabilized glucagon formulations are provided, in the form of a clear solution. The formulations include glucagon in a non-aqueous diluent and an antioxidant The diluent and antioxidant are selected to provide a glucagon formulation with increased stability when compared to glucagon without the anti-oxidant and/or the diluent and which shows a comparable onset of action and duration of glucose response. The compositions can be used to treat subjects with very low blood sugar (severe hypoglycemia) that can happen in subjects who have diabetes and use insulin.
1 . A stabilized glucagon formulation comprising a pharmaceutically acceptable antioxidant in a non-aqueous diluent effective to stabilize the glucagon.
2 . The formulation of claim 1 , wherein the antioxidant is selected from the group consisting of propyl gallate, butylated hydroxylanisole, butylated hydroxytoluene, d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), methionine and combinations thereof.
3 . The formulation of claim 1 , comprising TPGS in a concentration ranging from 2-20 mg/ml.
4 . The pharmaceutical preparation according to claim 1 , further comprising a pharmaceutical acceptable excipient.
5 . The formulation of claim 1 , comprising water in an amount ranging from 0 to 5%.
6 . The formulation of claim 5 , comprising water in an amount ranging from 1-3%.
7 . The formulation of claim 1 , wherein the non aqueous diluent is selected from the group consisting of propylene glycol (“PG”) and diethylene glycol monoethyl ether (TRANSCUTOL® (“TC”)).
8 . The formulation of claim 7 , wherein the ratio of PG:TC in the formulation is from 1:4 to 4:1.
9 . The formulation of claim 8 wherein the ratio of PG:TC in the formulation is 1:1.
10 . The formulation of claim 2 , comprising propyl gallate in a concentration ranging from 0.01-10 mg/ml.
11 . The formulation of claim 2 , comprising methionine in a concentration range between 0.05-10 mg/ml.
12 . The formulation of claim 1 comprising glucagon in a concentration ranging from 0.4-4 mg/ml.
13 . The formulation of claim 12 , wherein the pH of the formulation is in a range from 2-4 or 8-9.
14 . The formulations of claim 1 , wherein the formulation maintain at least 80% glucagon content as measured by reverse phase high performance liquid chromatography following agitation of 15 min per day at 50 revolutions per minute (rpm) at least 7 days.
15 . The formulation of claim 14 wherein the formulation maintains at least 80% glucagon content following agitation of 15 min per day at 50 revolutions per minute (rpm) at least 28 days.